Vitruvias Therapeutics, Inc Issues Nationwide Recall of One Lot of Thyroid Tablets, USP 30 mg Due to Potential Super Potency
Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.
Why it matters for dental
Dental practices that dispense or prescribe compounded thyroid tablets for patients with hypothyroidism should immediately quarantine and return Lot 504950 30 mg tablets, as super-potency could trigger arrhythmias or angina that complicate in-office procedures.
Key points
- Recall affects one specific lot (Lot No. 504950) of Thyroid Tablets, USP 30 mg; all other lots are unaffected.
- Super-potent thyroid hormone can increase heart rate and blood pressure—heightening risk of cardiac events during local-anesthetic or sedation dentistry.
- Action required: inspect inventory, isolate lot 504950, and follow return instructions; no FDA enforcement action is indicated at this time.
- Practices with in-house pharmacies or dispensing programs bear primary compliance responsibility for patient notification and retrieval.
Who should care
Read the original on FDA Recalls
Full reporting and any paywall content live on fda.gov. We summarize and score; we do not republish.
Related
- ·Business
Why the dental assistant shortage could get worse
- ·Business
US Oral Surgery Management exec on M&A: ‘We’ve had to be even more disciplined’
- ·Research
Vertical dimension of occlusion restoration using a digital injectable composite resin technique: A 5-year clinical follow-up
- ·Research
A digitally guided workflow integrating tooth preparation and restoration positioning for minimally invasive veneer and partial-coverage restorations: A dental technique